369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+ Anti-HER2 therapy+ endocrine therapy (ET) vs. anti-HER2 therapy+ ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)
Journal article published in 2018 by
S. Loibl,
O. Metzger,
Sj Mandrekar,
C. Mundhenke,
S. Seiler,
P. Valagussa,
A. DeMichele,
E. Lim 
,
D. Tripathy,
Ep Winer
,
D. Tripathy,
Ep Winer
